10-Q: BioAdaptives Inc. Reports Third Quarter 2024 Results with Increased Net Loss and Ongoing Financial Challenges

BioAdaptives Inc. reported a net loss of $527,373 for the nine months ended September 30, 2024, an increase from the $444,165 loss in the same period of 2023, alongside ongoing concerns about its ability to continue as a going concern.

Summary

• BioAdaptives Inc. reported a net loss of $37,649 for the three months ended September 30, 2024, compared to a net loss of $13,061 for the same period in 2023.
• The company's net loss for the nine months ended September 30, 2024, was $527,373, an increase from the $444,165 loss reported for the same period in 2023.
• The increase in net loss is primarily attributed to an impairment loss of patent and write-off of inventories recorded as cost of revenue.
• The company's revenue for the three months ended September 30, 2024, was $0, compared to $15,649 in the same period of 2023.
• Revenue for the nine months ended September 30, 2024, was $12,669, a decrease from $21,364 in the same period of 2023.
• Operating expenses for the three months ended September 30, 2024, were $121,941, compared to $96,863 in the same period of 2023.
• Operating expenses for the nine months ended September 30, 2024, were $268,781, compared to $175,257 in the same period of 2023.
• The company's cash balance as of September 30, 2024, was $43,893, a decrease from $60,776 at the end of 2023.
• The company has a working capital deficit of $1,805,361 as of September 30, 2024.
• The company has issued 1,231,728,974 common shares as of November 15, 2024.
• The company issued 4,000,000 shares of Series D Preferred Stock during the nine months ended September 30, 2024.
• The company converted notes with principal amounts of $63,250 and accrued interest of $4,727 into 335,968,749 shares of common stock during the nine months ended September 30, 2024.

Sentiment

Score: 2

Explanation: The document paints a very negative picture of the company's financial health, with increasing losses, declining revenue, a working capital deficit, and a going concern warning. The company's reliance on external parties for product development and marketing, coupled with material weaknesses in internal controls, further contribute to the negative sentiment.

Positives

• The company is reformulating its product line and plans to launch new products in the third quarter of 2024.
• The company has expanded its sales efforts for the Lung Flute to medical communities, pharmacies, gyms, athletic clubs, and senior communities.
• The company is exploring agreements with other medical device manufacturers and marketing companies.
• The company is conducting a survey on the use of PluriPain for Gadolinium Deposition Disease with promising early results.
• The company has appointed an exclusive distributor for its equine line of products.

Negatives

• The company has incurred losses since inception and has an accumulated deficit of $8,791,518 as of September 30, 2024.
• The company has a working capital deficit of $1,805,361 as of September 30, 2024.
• The company's revenue decreased significantly compared to the previous year.
• The company's operating expenses have increased significantly.
• The company has insufficient cash to operate its business at the current level for the next twelve months.
• The company has identified material weaknesses in its internal control over financial reporting.
• The company is in default on certain obligations.

Risks

• The company's ability to continue as a going concern is in doubt due to its losses and working capital deficit.
• The company's ability to raise additional capital through the future issuances of common stock is unknown.
• The company's success is contingent upon obtaining additional financing.
• The company has very limited experience in marketing and has yet to develop reliable sales expectations and forecasting.
• The company is reliant on marketing and distributing products developed and owned by others.
• The company does not own the formulations for its key products and manufactures and markets them under an agreement with the developer that requires payment of a royalty and license agreement.
• The company is in default on certain obligations.
• The company has identified material weaknesses in its internal control over financial reporting.

Future Outlook

The company plans to issue additional shares of common stock for cash and services during the next 12 months to mitigate the risk related to its going concern status. The company is also focused on expanding its marketing efforts and launching new products.

Management Comments

• Management believes that international sales represent a significant future growth opportunity.
• Management expects greater sales activities for the Lung Flute in the last two quarters of 2024.
• Management is actively seeking a workable, efficient formula to grow consumer engagement and product sales.

Industry Context

The company operates in the nutraceutical and medical device industries, which are characterized by intense competition and evolving consumer preferences. The company's focus on natural ingredients and proprietary formulations aligns with current health and wellness trends. The company's expansion into the medical device market with the Lung Flute is a strategic move to diversify its revenue streams.

Comparison to Industry Standards

• BioAdaptives' financial performance is significantly below industry standards for companies of similar size and stage.
• Many nutraceutical companies are experiencing growth in revenue and profitability, while BioAdaptives is experiencing declining revenue and increasing losses.
• Companies like Herbalife and Nu Skin, which operate in the direct sales and nutraceutical space, have significantly higher revenue and profitability.
• Medical device companies like Medtronic and Stryker have robust R&D and manufacturing capabilities, which BioAdaptives lacks.
• BioAdaptives' reliance on third-party manufacturers and distributors is a common practice in the industry, but its lack of control over product formulations and marketing is a significant disadvantage.
• The company's working capital deficit and going concern status are not typical for companies in the nutraceutical and medical device industries.

Related Party Transactions

• The company repaid notes payable to a related party of $0 and $3,300 and recognized interest of $134 and $54, respectively, during the nine months ended September 30, 2024 and 2023.
• The company issued 150,000 shares of Series B preferred stock to settle a note payable of $860 and accrued interest of $640 with a related party.
• As of September 30, 2024, the company owed Dr. Edward E. Jacobs, M.D., its CEO, $2,377.
• The company owes a salary of $300,000 related to employment agreements.

Stakeholder Impact

• Shareholders are at risk due to the company's financial instability and going concern status.
• Employees may be affected by potential cost-cutting measures or layoffs due to the company's financial challenges.
• Customers may be impacted by potential changes in product availability or quality.
• Suppliers may face increased risk of non-payment due to the company's financial difficulties.
• Creditors are at risk due to the company's default on certain obligations.

Next Steps

• The company plans to issue additional shares of common stock for cash and services.
• The company intends to expand its marketing efforts and launch new products.
• The company will continue to seek additional financing to fund operations.
• The company plans to implement changes to improve its internal control over financial reporting.

Key Dates

Keywords

BioAdaptives, Nutraceuticals, Medical Devices, Financial Results, Going Concern, Preferred Stock, Convertible Notes, Operating Expenses, Net Loss, Revenue, Internal Control, Marketing, Product Development